The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Healthy

Interventions

DRUG

PF 06260414 solid dose formulation

Single dose of 30 mg PF-06260414 given under fed/fasted conditions

DRUG

PF-06260414 nanosuspension

Single dose of 30 mg PF-06260414 given under fasted conditions

Trial Locations (1)

Pfizer New Haven Clinical Research Unit, New Haven